A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. - Wikidata - awgldk - TriplyDB

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

http://www.wikidata.org/entity/Q39319420

about

Micelle-like nanoparticles as carriers for DNA and siRNA The combined effects of irradiation and herpes simplex virus type 1 infection on an immortal gingival cell line.Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.Bioengineering strategies for designing targeted cancer therapies Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors.RNA interference in the treatment of colon cancer.Recent advances in delivery of drug-nucleic acid combinations for cancer treatment Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art.Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.siRNA nanoparticles: the future of RNAi therapeutics for oncology?X-linked inhibitor of apoptosis-associated factor l (XAFl) enhances the sensitivity of colorectal cancer cells to cisplatin.Tackling breast cancer chemoresistance with nano-formulated siRNA.Carbohydrate-based amphiphilic nano delivery systems for cancer therapy.The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.Evaluation of the potential of a simplified co-delivery system with oligodeoxynucleotides as a drug carrier for enhanced antitumor effect.siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin

P2860

Q27001558-635C622A-C7D3-4591-8CCD-550DAA5106A7 Q33928172-E71E8BC7-D76F-4B70-8AF9-59156805A47E Q33934922-E378FBB4-F58E-4460-87C6-0ED1638792BB Q34194191-09093E98-DD3F-44DD-854C-6AC278330361 Q34622662-A3DA4036-8994-4614-AD24-54576D1C546D Q35924301-E9ED41BE-5415-4AD5-97A8-8B5FFDE5C09B Q36748360-1B7254FD-516D-40AC-8744-34371B47C7BF Q37438008-AA07FDE9-16EE-4F11-826A-2E9788A1D612 Q38095807-C82D8C88-BCF6-4E74-93FC-088B975A703C Q38102522-4B014407-7D9A-4D69-8CAC-8F7A200449E6 Q38165880-C2056BD3-7937-4A12-B419-C8FD106C4E7E Q38693952-D77D8EFA-940E-4229-BC34-081BFF7BBE1E Q38856533-4D818F87-57C6-40E7-8525-B2EC0F2FB68A Q38938368-26968975-0E7F-4E36-8C20-59537F6C7337 Q38943031-D61F7B1C-E57F-4197-9775-433A142BCA0B Q38959517-E9A7F55F-84E8-4477-B887-467DAB5964B2 Q38974572-AF9D18C8-2B8E-4450-9463-F4D4E57BDF87 Q50994403-97DA5504-B06D-4A8D-A5EF-D910BC931196 Q54967223-63467D25-C887-4CD6-B3BA-2E9CDF8F5CF6 Q58795137-6009264A-0728-4401-9C0B-72F308214BBA

P2860

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

http://www.wikidata.org/entity/Q39319420

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

@en

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

@nl

type

label

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

@en

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

@nl

prefLabel

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

@en

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

@nl

P1433

Q39319420-45C795F6-8B0B-41F5-BCE8-47A1A57E4216

P1476

Q39319420-FFA5A029-19F9-4E16-BF25-C398C793D557

P2093

Q39319420-122012C5-D791-4A31-AB6D-62587EED32AE

Q39319420-7A8BE951-E049-4B97-A3B5-03E8BB8CD51F

Q39319420-9EBEC9AD-71A3-45AC-8ABE-ED82D3346785

Q39319420-E58FC1AC-39E7-4937-8A7E-3BEFB7375250

Q39319420-EE9C642A-2B5A-42C4-90DE-00439653789D

P2860

Q39319420-02829344-4F1E-4E03-95DA-FD2B16E0F064

Q39319420-14174637-250B-476A-9382-9CC3D5E48D3F

Q39319420-19CE11C3-1F39-4B78-88A6-9D3309671211

Q39319420-1EC8D941-6364-4AA2-AF5B-0DDA054812DE

Q39319420-295F38EC-164E-45B5-A1CB-47BDDA7EF4D8

Q39319420-2A811B54-172F-4DB9-B069-5F0DEC7D3800

Q39319420-302B747F-78EC-4929-BBAC-B0C01D2A9DE4

Q39319420-3456A42B-9E30-451F-96C9-FC28FA848F5E

Q39319420-37CDE6B3-A33B-4C2B-903B-66D230C72168

Q39319420-466BF51D-44B0-438E-B25F-3693948A9C87

P304

Q39319420-4614A043-59E4-40D7-B702-7E2FA7A176FF

P31

Q39319420-FF0C3381-E685-4311-BC85-85DCA3E134B3

P356

Q39319420-DA8F0B5C-20DC-448F-9D5B-86DC6EAA3061

P433

Q39319420-94681D44-B534-43D0-85D6-AD43C6FA93AB

P478

Q39319420-9C23335D-3F90-433B-9524-EAF070134DB2

P50

Q39319420-C83B4A05-7504-4BE0-B331-418A41D10E1B

P577

Q39319420-D2B5C4C6-CF89-4AD3-B504-01553758F093

P5875

Q39319420-8260C884-F3D8-4DC9-8DE1-9962C7E7DCE5

P698

Q39319420-8A94084D-09FC-4A17-93BC-FE63F75B9A61

P921

Q39319420-3B411C44-FA7D-4B06-8E1E-23A87D8D1CCE

P932

Q39319420-DC385CB6-C388-438C-A47D-DD9F42024039

P356

P1433

Molecular Therapy

P1476

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA

@en

P2093

Hiroshi Kiwada

http://www.w3.org/2001/XMLSchema#string

Kazuya Nakamura

http://www.w3.org/2001/XMLSchema#string

Mariko Matsunaga

http://www.w3.org/2001/XMLSchema#string

Tatsuhiro Ishida

http://www.w3.org/2001/XMLSchema#string

Yusuke Doi

http://www.w3.org/2001/XMLSchema#string

P2860

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.

LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.

Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.

siRNA-mediated gene silencing in vitro and in vivo.

RNA interference--2001.

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

P304

2040-2047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2011.174

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51606691

http://www.w3.org/2001/XMLSchema#string

P698

21878904

http://www.w3.org/2001/XMLSchema#string

P921

P932

3222530

http://www.w3.org/2001/XMLSchema#string